sing BCG vaccine to strengthen the immune system in the elderly and improve the response to influenza vaccine. A randomized clinical trial. - BCG-DENMARK-INFLUENZA

niversity of Southern Denmark, Bandim Health Project0 个研究点目标入组 300 人开始时间: 2021年6月25日最近更新: 2022年8月8日

适应症

试验速览

暂无简介。

•Elderly people > 65 years and eligible for seasonal influenza vaccination. Participants must have access to ‘e-Boks’.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 300

•Known allergy to (components of) the BCG vaccine or serious adverse events in relation to prior BCG administration
•Previous Mycobacterium tuberculosis (M. tuberculosis) infection or known active or latent infection with M. tuberculosis or other mycobacterial species
•Fever (>38 C) within the past 24 hours or suspicion of active viral or bacterial infection
•Vaccination with other live attenuated vaccine within the last 4 weeks
•Severely immunocompromised subjects. This exclusion category comprises:
•Subjects with known infection with the human immunodeficiency virus (HIV)
•Subjects with solid organ transplantation or bone marrow transplantation
•Subjects under chemotherapy
•Subjects with primary immunodeficiency
•Treatment with any anti-cytokine therapy within the last year
•Treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months
•Active solid or non-solid malignancy or lymphoma within the prior two years
•Subjects who do not have access to e-Boks.
•Participant in BCG-DENMARK-SENIOR study

发起方

niversity of Southern Denmark, Bandim Health Project